Management of metabolic complications of therapy.
Considerable efforts are underway to define effective strategies for the treatment of metabolic complications of HIV therapy. Clearly these problems dominate the overall approach to treatment of HIV infection in the settings where antiretroviral agents are accessible. While progress has been made it has been slow, and accompanied by disappointments. There are currently no effective treatments for lipoatrophy, and while treatments for dyslipidemia have been described, in most cases the improvement is incomplete. While these efforts must continue it is hoped that a new focus on prevention of metabolic complications will begin to emerge in the year ahead.
Currier
Judith
J
University of California Los Angeles, Department of Medicine, Division of Infectious Diseases, 37-121 CHS, Los Angeles CA 90095, USA. JSCurrier@mednet.ucla.edu
D019380:Anti-HIV Agents / Q000009:adverse effects*; D003924:Diabetes Mellitus, Type 2 / Q000139:chemically induced; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced / Q000188:drug therapy; D008060:Lipodystrophy / Q000139:chemically induced / Q000188:drug therapy; D008659:Metabolic Diseases / Q000139:chemically induced* / Q000188:drug therapy
D019380:Anti-HIV Agents